The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Open accessAbstract
Purpose: This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma. Patients and Methods: Patients initially received oral sorafenib 400 mg twice daily during the initial run-in period. After 12 weeks, patients with changes in bidimensional tumor measurements that were less than 25% from baseline were randomly assigned to sorafenib or placebo for an additional 12 weeks; patients with ≥ 25% tumor shrinkage continued open-label sorafenib; patients with ≥ 25% tumor growth discontinued treatment. The primary end point was the percentage of randomly assigned patients remaining progression free at 24 weeks after the initiation of sorafenib. Results: Of 202 patients treated during the run-in period, 73 patients had tumor shrinkage of ≥ 25%. Sixty-five patients with stable disease at 12 weeks were randomly assigned to sorafenib (n = 32) or placebo (n = 33). At 24 weeks, 50% of the sorafenib-treated patients were progression free versus 18% of the placebo-treated patients (P = .0077). Median progression-free survival (PFS) from randomization was significantly longer with sorafenib (24 weeks) than placebo (6 weeks; P = .0087). Median overall PFS was 29 weeks for the entire renal cell carcinoma population (n = 202). Sorafenib was readministered in 28 patients whose disease progressed on placebo; these patients continued on sorafenib until further progression, for a median of 24 weeks. Common adverse events were skin rash/desquamation, hand-foot skin reaction, and fatigue; 9% of patients discontinued therapy, and no patients died from toxicity. Conclusion: Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Self-citationPrognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
Uretsky, B. F., Young, J. B., Shahidi, F. E., Yellen, L. G., Harrison, M. C., & Jolly, M. K. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90403-n · Cited by 582
Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 348
Self-citationClark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 339
Self-citationThe efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., Pandita-Gunawardena, N. D., Hogg, F., Clare, C., & Damms, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129990.32253.7b · Cited by 339
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
Self-citationWilhelm, S., & Chien, D.-S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393026 · Cited by 289
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
Hilger, R. A., Scheulen, M. E., & Strumberg, D. (2002) · Oncology Research and Treatment · doi:10.1159/000068621 · Cited by 265
Ratain, M. J., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.960 · Cited by 227
Self-citationRandomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents
Rosner, G. L., Stadler, W., & Ratain, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.126 · Cited by 201
Self-citationCibere, J., Kopec, J. A., Thorne, A., Singer, J., Canvin, J., Robinson, D., Pope, J. E., Hong, P., Grant, E., & Esdaile, J. M. (2004) · Arthritis Care & Research · doi:10.1002/art.20697 · Cited by 138
Randomized discontinuation trials: Utility and efficiency
Kopec, J. A., Abrahamowicz, M., & Esdaile, J. M. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90163-u · Cited by 134
Stadler, W. M., Rosner, G. L., Small, E. J., Hollis, D. R., Rini, B. I., Zaentz, S. D., Mahoney, J. F., & Ratain, M. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.44.150 · Cited by 83
Self-citationA Clinical Trial Design Avoiding Undue Placebo Treatment
Amery, W. K., & Dony, J. (1975) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1975.tb05919.x · Cited by 82
An alternative model for the evaluation of antitumor activity.
Lavin, P. T. (1981) · PubMed · Cited by 67
Vigabatrin withdrawal randomized study in children
Chiron, C., Dulac, O., & Gram, L. F. (1996) · Epilepsy Research · doi:10.1016/s0920-1211(96)00028-9 · Cited by 36
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Self-citationChoi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
Metadata
- Authors
- Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., Rowinsky, E., Abbruzzese, J. L., Xia, C., Simantov, R., Schwartz, B., & O'Dwyer, P. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-06-01
- Volume
- 24
- Issue
- 16
- Pages
- 2505-2512
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149026055
- Cited by
- 1,032
- References
- 24
- FWCI
- 138.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.